Impact of bariatric surgery on the absorption of lercanidipine
Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine
This study looks at how bariatric surgery affects how well the medication lercanidipine is absorbed in patients who have had weight loss surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Norwegian University of Science and Technology Academic / other |
| Locations | 1 site (Trondheim) |
| Trial ID | NCT03497156 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how bariatric surgery, specifically gastric bypass and sleeve gastrectomy, affects the pharmacokinetics of the medication lercanidipine in patients. It aims to understand changes in gastric pH, gastric emptying time, and gastrointestinal transit time that may influence the biological availability of this drug. By examining these factors, the study seeks to provide insights into how surgical interventions for obesity can alter medication absorption and effectiveness.
Who should consider this trial
Good fit: Ideal candidates are Norwegian citizens preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway.
Not a fit: Patients who have previously undergone resections in the gastrointestinal tract may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved medication management for patients undergoing bariatric surgery.
How similar studies have performed: While there is limited research on this specific topic, studies examining the pharmacokinetics of medications post-bariatric surgery have shown varying results, indicating a need for further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract
Where this trial is running
Trondheim
- St. Olavs University Hospital — Trondheim, Norway (Recruiting)
Study contacts
- Principal investigator: Magnus Strømmen, MSc — St. Olavs Hospital
- Study coordinator: Magnus Strømmen, MSc
- Email: magnus.strommen@stolav.no
- Phone: 0047 72829970
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.